UpdatesPlus-IBD - Jan 2014
The January issue of UpdatesPlus-IBD is now available. This month we feature:
- Janssen's investigational biomarker approach to guide the
selection of biologics
- New Humira data
- AdCom recommendation of vedolizumab and what this may mean
to clinical practice
- Novel biologic approaches including engineered bacteria and
colostrum antibodies for local delivery
- Two first in class pipeline entries
- Tyrosine kinase inhibition as a novel approach to IBD
If you have yet to receive this 81 slide issue and would like to see the summary of what is included please click here
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
J Cancer Res Ther 2013, 1(10):235-243 [Full text]
Bello-Rivero et al [contact]
Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale design of the combination of IFN-a2b and -γ based in their anti-proliferative synergism on several tumors cell lines identified adequate proportions to be combined to obtain the best clinical results. The potential mechanism of antitumoral effect was studied by qPCR mRNA quantification. HEBERPAG (anti-proliferative synergistic combination of co-formulated recombinant interferons-a2b and –γ) was used in clinical trials in adult patients with non-melanoma skin cancer. Trials were conducted after approval by the ethics review boards of the institutions participating in trials; and the patients gave their written informed consent to be enrolled in the studies and receive HEBERPAG. Results: HEBERPAG inhibits the proliferation of several tumor cell lines in vitro and in vivo. The combination has improved pharmacodinamic properties. Several clinical trials have demonstrated the efficacy of HEBERPAG in BCC, with excellent cosmetic effect and well tolerable, mild side effects. HEBERPAG was approved by State Control Center for Drug, Medical Equipment and Devises in Cuba, for the treatment of basal cell carcinoma of any subtype, size and localization, and adjuvant to other treatments, surgical or not. After 3-year follow-up, a recurrence rate of 0.03% was detected in treated patients. Conclusions: HEBERPAG is a novel formulation of IFNs, more potent than separated IFNs for the treatment of basal cell carcinoma, with more rapid and prolonged clinical effect and excellent cosmetic effect and safety profile.
For further information on this licensing option click here
